Dr Rachel McLoughlin, Prof Daniel Bradley and Prof Mani Ramaswami are all based at Trinity College Dublin (TCD) and have been jointly awarded €5.5m to further their various projects.
This includes McLoughlin’s research to help improve antibiotic-resistant Staphylococcus aureus (MRSA) treatment options, Bradley’s sequencing of the genome of ‘Atlantic-edge’ populations, and Ramaswami’s investigation into how the brain regulates access to feelings, perceptions and memories.
McLoughlin said: “The award will enable me to expand my research programme at TCD and enhance my reputation as a leader in my field.”
Ramaswami added that the award will support his interactions with scientists and institutions in India, USA and the UK as well as providing valuable new opportunities for students and young scientists in Ireland.
Dr Mairéad O’Driscoll, interim chief executive at the HRB, said: “You’re competing with some of the world’s best when you apply for Wellcome funding. So, these awards are a ringing endorsement of professors Bradley, Ramaswami and Dr McLoughlin.
“In the case of Dr McLoughlin, we are delighted that she can build on her previous HRB-funded work in the area of MRSA and the search for a vaccine for the superbug. I wish them all every success in their endeavours.”
The SFI-HRB-Wellcome Biomedical Research Partnership has funded biomedical research in Ireland since 2010, and aims to support outstanding researchers and innovative research programmes in biomedicine.
This article originally appeared on www.siliconrepublic.com and can be found at:
You'll find us responsive to your needs, proactive, professional and willing to go the extra mile.
We have 28 Offices worldwide helping support companies expand their operations in Ireland.